$198.26−4.22%Close 16 Nov 2026 · Market value $30.43B
About Illumina
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.
From Wikipedia, shared under CC BY-SA.
Company facts
| Ticker | ILMN · Nasdaq |
|---|
| Sector | Instruments |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 28 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1110803 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Keith Meister | Director | 4.2M · 2.8% | Open-market sale, 11 Nov 2026 |
|---|
| Jacob Thaysen | Chief Executive Officer · Director | 40.3K · < 1% | Shares withheld for tax, 5 Oct 2026 |
|---|
| Robert Epstein | Director | 22.1K · < 1% | Grant or award, 21 May 2025 |
|---|
| Frances Arnold | Director | 20.9K · < 1% | Grant or award, 21 May 2025 |
|---|
| Philip Schiller | Director | 20.1K · < 1% | Grant or award, 21 May 2026 |
|---|
| Gary Guthart | Director | 16.4K · < 1% | Grant or award, 21 May 2025 |
|---|
| Caroline Dorsa | Director | 15.2K · < 1% | Grant or award, 21 May 2026 |
|---|
| Susan Siegel | Director | 14.5K · < 1% | Grant or award, 21 May 2026 |
|---|
| Kevin Pegels | Chief of Global Operations | 13.1K · < 1% | Shares withheld for tax, 5 Nov 2026 |
|---|
| Ankur Dhingra | SVP, Chief Financial Officer | 13.1K · < 1% | Grant or award, 5 Mar 2026 |
|---|
| Scott Gottlieb | Director | 12.7K · < 1% | Grant or award, 21 May 2026 |
|---|
| Scott Ullem | Director | 8.6K · < 1% | Grant or award, 30 Sep 2026 |
|---|
| Anna Richo | Director | 6.5K · < 1% | Grant or award, 21 May 2026 |
|---|
| Everett Cunningham | SVP, Chief Commercial Officer | 4.7K · < 1% | Shares withheld for tax, 5 Jul 2025 |
|---|
| David King | Director | 0 · < 1% | Grant or award, 21 May 2026 |
|---|
| Ericksen Scott D | VP, Chief Accounting Officer | — | Sale under a 10b5-1 plan, 10 Nov 2026 |
|---|
| Barnard Steven | SVP, Chief Technology Officer | — | Shares withheld for tax, 5 Nov 2026 |
|---|
| Leckman Patricia | SVP, Chief People Officer | — | Shares withheld for tax, 5 Nov 2026 |
|---|
| Coletti Julie Ann | Chief Legal Officer | — | Grant or award, 8 Sep 2026 |
|---|
| Wedel Christensen Jakob | SVP, Strategy/Corp Development | — | Sale under a 10b5-1 plan, 18 Aug 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ILMN in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.